SAB-185 will be tested in people with mild or moderate COVID-19

Wednesday, April 21, 2021 Large NIH Clinical Trial Will Test Polyclonal Antibody Therapeutic for COVID-19 A trial to test a new high-potency fully-human polyclonal antibody therapeutic in people with mild or moderate cases of COVID-19 has begun enrolling participants. The ACTIV-2 master protocol, a placebo-controlled randomized clinical trial which has previously tested other therapeutics, has now begun testing SAB-185, developed by SAB Biotherapeutics, Inc. The therapeutic candidate was developed from SAB's platform, which uses genetically-engineered cattle to produce fully-human antibodies. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107